PPL-103 / Phoenix PharmaLabs - LARVOL DELTA

PPL-103: A mixed opioid partial agonist with desirable anti-cocaine properties. (PubMed, Prog Neuropsychopharmacol Biol Psychiatry) - "Operant responding for food, fentanyl and locomotor behavior were not altered at doses that decreased cocaine infusions...Surprisingly, PPL-103 reduced self-administration parameters and reinstatement in rats previously treated with the long-acting kappa receptor antagonist JDTic more potently than in non-JDTic treated animals, whereas naltrexone injected to rats subsequent to JDTic administration increased self-administration, suggesting that the partial mu agonist activity, rather than kappa agonism is important for reduction in cocaine taking and seeking. However, partial kappa activation seems to increase safety by limiting dysphoria, tolerance and addiction development. PPL-103 displays a desirable profile as a possible CUD pharmacotherapy."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry

Phoenix PharmaLabs Strengthens its Position as a Developer of Next Generation Pain Pharmaceuticals with the Acquisition of a Portfolio of NOP/Mu Agonist Compounds (Businesswire) - "Phoenix PharmaLab...today announced it has completed a license agreement with the University of Bath in England for exclusive rights to a portfolio of 25 NOP (Nociceptin) compounds...With both PPL-103 and the addition of PPL-138 to our portfolio, we believe we can help meet the unmet need for effective non-addicting treatment of moderate to severe pain."

Licensing / partnership • Pain